MedTrace Logo

A Phase I Study of Quadrivalent HPV Recombinant Vaccine

NCT03085381 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2018-09-14

No results posted yet for this study

Summary

To evaluate the safety and primary immunogenicity of the quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (hansenula polymorpha) in Chinese female subjects aged 9-45 years.

Conditions

  • HPV Infections

Interventions

BIOLOGICAL

HPV vaccine

BIOLOGICAL

Placebo

Sponsors & Collaborators

  • Shanghai Bovax Biotechnology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Zhaojun Mo, Master · Guangxi Centers for Disease Control and Prevention

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
9 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2017-10-31
Completion
2018-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03085381 on ClinicalTrials.gov